MedTrace Logo

Using 4D Urinary Proteomics to Predict and Evaluate Treatment Response in Colorectal Cancer

NCT06904677 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2025-11-28

No results posted yet for this study

Summary

The goal of this observational study is to learn how well urinary proteins can predict treatment response in patients with locally advanced colorectal cancer (LACC) undergoing neoadjuvant therapy. The main question it aims to answer is:

Can urinary protein markers help predict and evaluate how patients with LACC respond to neoadjuvant therapy?

Participants diagnosed with LACC will provide urine samples before and after neoadjuvant therapy. These samples will be analyzed using 4D deep urinary proteomics and machine learning to identify proteins linked to treatment response. Some participants' tumor tissues will also be used to create organoid models for further testing.

Conditions

  • Colorectal Cancer (CRC)
  • Neoadjuvant Therapy
  • Proteomics

Sponsors & Collaborators

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2027-05-01
Completion
2029-05-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06904677 on ClinicalTrials.gov